[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: UnitedHealth Stock Drops After Earnings Miss, Guidance Cut",
    "summary": "The S&P 500 ticked 0.1% higher on Thursday, April 17, wrapping up a shortened week that focused on earnings and the Federal Reserve chair's comments on likely tariff impacts.",
    "url": "https://finnhub.io/api/news?id=6d3bbff0e528aa9182bde214ba3066c00a3cb3a385010ee01d6423b6fbf8f645",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744924097,
      "headline": "S&P 500 Gains and Losses Today: UnitedHealth Stock Drops After Earnings Miss, Guidance Cut",
      "id": 133964507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 ticked 0.1% higher on Thursday, April 17, wrapping up a shortened week that focused on earnings and the Federal Reserve chair's comments on likely tariff impacts.",
      "url": "https://finnhub.io/api/news?id=6d3bbff0e528aa9182bde214ba3066c00a3cb3a385010ee01d6423b6fbf8f645"
    }
  },
  {
    "ts": null,
    "headline": "EXTRA: Analysts hail outstanding data for Eli Lilly's weight loss drug",
    "summary": "EXTRA: Analysts hail outstanding data for Eli Lilly's weight loss drug",
    "url": "https://finnhub.io/api/news?id=3ae2769e36c346c3b792d0abd6db57973d8b048956f38ab05eaa511e21dd0df5",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744922951,
      "headline": "EXTRA: Analysts hail outstanding data for Eli Lilly's weight loss drug",
      "id": 133960350,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3ae2769e36c346c3b792d0abd6db57973d8b048956f38ab05eaa511e21dd0df5"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth Woes Aren’t Dragging Down the Entire Sector. Here’s Why.",
    "summary": "Weak results from UnitedHealth arern’t hurting all healthcare stocks. Eli Lilly is soaring on promising weight-loss pill news. Other healthcare stocks remain healthy too.",
    "url": "https://finnhub.io/api/news?id=a0302cd856d7850976495c74501dd5554267e458e63cfa5936461d119be09609",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744922040,
      "headline": "UnitedHealth Woes Aren’t Dragging Down the Entire Sector. Here’s Why.",
      "id": 133964508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weak results from UnitedHealth arern’t hurting all healthcare stocks. Eli Lilly is soaring on promising weight-loss pill news. Other healthcare stocks remain healthy too.",
      "url": "https://finnhub.io/api/news?id=a0302cd856d7850976495c74501dd5554267e458e63cfa5936461d119be09609"
    }
  },
  {
    "ts": null,
    "headline": "How Eli Lilly's GLP-1 pill could transform the weight-loss space",
    "summary": "Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=5a75fc8e2c154b4bdbeee163cf27a94ea27f8a6c04554bfe285f957de622badb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744921780,
      "headline": "How Eli Lilly's GLP-1 pill could transform the weight-loss space",
      "id": 133964509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=5a75fc8e2c154b4bdbeee163cf27a94ea27f8a6c04554bfe285f957de622badb"
    }
  },
  {
    "ts": null,
    "headline": "NEW YORK MARKET CLOSE: Shares mixed as Trump targets Fed Chair Powell",
    "summary": "NEW YORK MARKET CLOSE: Shares mixed as Trump targets Fed Chair Powell",
    "url": "https://finnhub.io/api/news?id=21df5d0c6a8ca41466003dba148226b33b2b05d1468c18d29055e846d44ddfa4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744921542,
      "headline": "NEW YORK MARKET CLOSE: Shares mixed as Trump targets Fed Chair Powell",
      "id": 133960109,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=21df5d0c6a8ca41466003dba148226b33b2b05d1468c18d29055e846d44ddfa4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill",
    "summary": "Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.",
    "url": "https://finnhub.io/api/news?id=0e7186c8ed378fa54ffb547992d83969d425a9e27103d452e869602ef9178217",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744920633,
      "headline": "Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill",
      "id": 133964510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.",
      "url": "https://finnhub.io/api/news?id=0e7186c8ed378fa54ffb547992d83969d425a9e27103d452e869602ef9178217"
    }
  },
  {
    "ts": null,
    "headline": "Equity Markets Mixed as Trump Calls for Interest Rate Cuts",
    "summary": "US benchmark equity indexes are on track to close mixed on Thursday as investors weigh President Don",
    "url": "https://finnhub.io/api/news?id=3fdae447a3d0bc479b959916f0fe036508b0081d987ae42efe69202ef1f92608",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744919267,
      "headline": "Equity Markets Mixed as Trump Calls for Interest Rate Cuts",
      "id": 133964511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes are on track to close mixed on Thursday as investors weigh President Don",
      "url": "https://finnhub.io/api/news?id=3fdae447a3d0bc479b959916f0fe036508b0081d987ae42efe69202ef1f92608"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race",
    "summary": "Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is being overtaken by rival Eli Lilly’s rapidly advancing pipeline.",
    "url": "https://finnhub.io/api/news?id=5bcc07d7a5fcdc7c1ceea3c681c1b530f6a2f8bbf6730f3fea0db0a9fff9e14d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744915289,
      "headline": "Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race",
      "id": 133964512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is being overtaken by rival Eli Lilly’s rapidly advancing pipeline.",
      "url": "https://finnhub.io/api/news?id=5bcc07d7a5fcdc7c1ceea3c681c1b530f6a2f8bbf6730f3fea0db0a9fff9e14d"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth Sell-Off Drags Dow Lower Intraday; Markets Weigh Trump's Remarks",
    "summary": "US benchmark equity indexes were mixed intraday, weighed down by a post-earnings sell-off in UnitedH",
    "url": "https://finnhub.io/api/news?id=902664477ba10a7348f1f798c864a41dc6f906ec255424e64e256f4bd023700d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744914362,
      "headline": "UnitedHealth Sell-Off Drags Dow Lower Intraday; Markets Weigh Trump's Remarks",
      "id": 133964513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were mixed intraday, weighed down by a post-earnings sell-off in UnitedH",
      "url": "https://finnhub.io/api/news?id=902664477ba10a7348f1f798c864a41dc6f906ec255424e64e256f4bd023700d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade",
    "summary": "U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.",
    "url": "https://finnhub.io/api/news?id=a79e44365e50431a652f8f9a26056dac23a3ac816c70784c8d39a1c79d79fe1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744912452,
      "headline": "Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade",
      "id": 133959513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.",
      "url": "https://finnhub.io/api/news?id=a79e44365e50431a652f8f9a26056dac23a3ac816c70784c8d39a1c79d79fe1a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Partners With BigHat And Achieves Phase 3 Success With Orforglipron",
    "summary": "Eli Lilly (NYSE:LLY) experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The company's share price was likely influenced by its strategic collaboration with BigHat Biosciences and positive results from its ACHIEVE-1 Phase 3 trial for orforglipron. These positive developments countered the market's broader dip caused by tech sector weaknesses and economic concerns following recent economic tariff suggestions influencing investor sentiments. These...",
    "url": "https://finnhub.io/api/news?id=a0e9bff8b820b1ab658ea5a786e276471a1cd8a99ada0b3596d7d37bbea21584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744911043,
      "headline": "Eli Lilly (NYSE:LLY) Partners With BigHat And Achieves Phase 3 Success With Orforglipron",
      "id": 133958464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The company's share price was likely influenced by its strategic collaboration with BigHat Biosciences and positive results from its ACHIEVE-1 Phase 3 trial for orforglipron. These positive developments countered the market's broader dip caused by tech sector weaknesses and economic concerns following recent economic tariff suggestions influencing investor sentiments. These...",
      "url": "https://finnhub.io/api/news?id=a0e9bff8b820b1ab658ea5a786e276471a1cd8a99ada0b3596d7d37bbea21584"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide",
    "summary": "Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.",
    "url": "https://finnhub.io/api/news?id=72eb14d2b57b86c29ffa7b80ee9a0dc2746f926cccebbc562434e85c3b863209",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744908388,
      "headline": "Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide",
      "id": 133958465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.",
      "url": "https://finnhub.io/api/news?id=72eb14d2b57b86c29ffa7b80ee9a0dc2746f926cccebbc562434e85c3b863209"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More",
    "summary": "The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points as UnitedHealth Group shares plunged.",
    "url": "https://finnhub.io/api/news?id=365a9d7a258d0c5a74e7c579c6f7ee816a4bc66a9cfc7968cad6760ef16bcb0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744908346,
      "headline": "Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More",
      "id": 133958380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points as UnitedHealth Group shares plunged.",
      "url": "https://finnhub.io/api/news?id=365a9d7a258d0c5a74e7c579c6f7ee816a4bc66a9cfc7968cad6760ef16bcb0a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
    "summary": "Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.  Orforglipron is a GLP-1 receptor agonist that works similarly to medications like Novo’s Ozempic.  The pill mimics the effects of the hormone glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar levels.",
    "url": "https://finnhub.io/api/news?id=12f7cf6d364bebddd83e0fd8555e78798e720d27a7b2fd3fc6c9cff5e031b78a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744907940,
      "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
      "id": 133958467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.  Orforglipron is a GLP-1 receptor agonist that works similarly to medications like Novo’s Ozempic.  The pill mimics the effects of the hormone glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar levels.",
      "url": "https://finnhub.io/api/news?id=12f7cf6d364bebddd83e0fd8555e78798e720d27a7b2fd3fc6c9cff5e031b78a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial",
    "summary": "Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.",
    "url": "https://finnhub.io/api/news?id=33ae0d2cde39afe3ba58f0e3493ffa6262fd619b0faf0d3305df67526fc2135d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744906642,
      "headline": "Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial",
      "id": 133958468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.",
      "url": "https://finnhub.io/api/news?id=33ae0d2cde39afe3ba58f0e3493ffa6262fd619b0faf0d3305df67526fc2135d"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Eli Lilly (LLY) Stock Rocketing Higher Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes. The stock's reaction suggested that investors were optimistic that, if approved, Lilly could scale production quickly and tap into the fast-growing diabetes and obesity markets.",
    "url": "https://finnhub.io/api/news?id=adc855d9fad0bd1ef5731ccd1b757da345bc7ad06872c212b7e126077e384d53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744905685,
      "headline": "Why Is Eli Lilly (LLY) Stock Rocketing Higher Today",
      "id": 133958469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes. The stock's reaction suggested that investors were optimistic that, if approved, Lilly could scale production quickly and tap into the fast-growing diabetes and obesity markets.",
      "url": "https://finnhub.io/api/news?id=adc855d9fad0bd1ef5731ccd1b757da345bc7ad06872c212b7e126077e384d53"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Google Found Liable on 3 of 4 Counts in Antitrust Case; UnitedHealth Shares Tumble on Revenue Miss, Guidance Cut",
    "summary": "The Dow Jones Industrial Average was down around 1.2%, driven in part by UnitedHealth Group's (UNH)",
    "url": "https://finnhub.io/api/news?id=c2acec449d3c2391563c089cc76924033cc72bc794c17c46e4f366b89457e106",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744905254,
      "headline": "Top Midday Stories: Google Found Liable on 3 of 4 Counts in Antitrust Case; UnitedHealth Shares Tumble on Revenue Miss, Guidance Cut",
      "id": 133958384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was down around 1.2%, driven in part by UnitedHealth Group's (UNH)",
      "url": "https://finnhub.io/api/news?id=c2acec449d3c2391563c089cc76924033cc72bc794c17c46e4f366b89457e106"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Rockets 15% After Solidifying Its Lead For A Weight-Loss Pill",
    "summary": "Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.",
    "url": "https://finnhub.io/api/news?id=bf6b737ef7f8df328eb4d1e35175c6c216815054c09db146db73f7cfe475d66d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744903473,
      "headline": "Eli Lilly Rockets 15% After Solidifying Its Lead For A Weight-Loss Pill",
      "id": 133958471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.",
      "url": "https://finnhub.io/api/news?id=bf6b737ef7f8df328eb4d1e35175c6c216815054c09db146db73f7cfe475d66d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars",
    "summary": "The first GLP-1 pill could be in medicine cabinets sooner than expected.",
    "url": "https://finnhub.io/api/news?id=0d006e1398a0f52f930f1d0be3ca63e95d644ab7d18754472d0c1b3c0fa0fffe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744903245,
      "headline": "Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars",
      "id": 133958472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The first GLP-1 pill could be in medicine cabinets sooner than expected.",
      "url": "https://finnhub.io/api/news?id=0d006e1398a0f52f930f1d0be3ca63e95d644ab7d18754472d0c1b3c0fa0fffe"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook",
    "summary": "On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock plunges after the company's earnings fell short of analyst expectations. Eli Lilly (LLY) stock surges after positive results about its weight-loss pill trial. Taiwan Semiconductor Manufacturing Company (TSM) stock is in focus after the company reported earnings and maintained its 2025 forecast despite new chip export restrictions. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=aa9af89ae8e13d61bef0ac434c03a07448b43fb622963c21611a8fd7d81ab4ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744902938,
      "headline": "UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook",
      "id": 133958473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock plunges after the company's earnings fell short of analyst expectations. Eli Lilly (LLY) stock surges after positive results about its weight-loss pill trial. Taiwan Semiconductor Manufacturing Company (TSM) stock is in focus after the company reported earnings and maintained its 2025 forecast despite new chip export restrictions. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=aa9af89ae8e13d61bef0ac434c03a07448b43fb622963c21611a8fd7d81ab4ec"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): Among the Innovative Healthcare Stocks to Watch in 2025",
    "summary": "We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other innovative healthcare stocks to watch in 2025. In the US, healthcare costs and prices have been increasing. According to […]",
    "url": "https://finnhub.io/api/news?id=aad5d2298bc1544edff1dcf022e9a77f78c8fb241bf4bb5d51302f05f3a82e94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744901909,
      "headline": "Eli Lilly and Company (LLY): Among the Innovative Healthcare Stocks to Watch in 2025",
      "id": 133958474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other innovative healthcare stocks to watch in 2025. In the US, healthcare costs and prices have been increasing. According to […]",
      "url": "https://finnhub.io/api/news?id=aad5d2298bc1544edff1dcf022e9a77f78c8fb241bf4bb5d51302f05f3a82e94"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Soars as Oral Diabetes Pill Hits Targets in Phase 3",
    "summary": "Lilly's once-daily diabetes pill showed strong A1C and weight-loss results, with approval filings expected in 2025--2026",
    "url": "https://finnhub.io/api/news?id=3d3db91afafb7d60a954646477a67631118a1dc88589ec9b4346bbd4a0f1c736",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744901688,
      "headline": "Eli Lilly Soars as Oral Diabetes Pill Hits Targets in Phase 3",
      "id": 133958475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's once-daily diabetes pill showed strong A1C and weight-loss results, with approval filings expected in 2025--2026",
      "url": "https://finnhub.io/api/news?id=3d3db91afafb7d60a954646477a67631118a1dc88589ec9b4346bbd4a0f1c736"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Investigational Obesity Pill Helps Control Glucose Levels, Reduce Weight; Shares Rally",
    "summary": "Eli Lilly (LLY) said Thursday that its investigational obesity pill helped diabetes patients achieve",
    "url": "https://finnhub.io/api/news?id=98868d0ea439aabb743b670acad40d9100051044327b0b3fbfddc987bdc152bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744901319,
      "headline": "Eli Lilly Investigational Obesity Pill Helps Control Glucose Levels, Reduce Weight; Shares Rally",
      "id": 133958476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Thursday that its investigational obesity pill helped diabetes patients achieve",
      "url": "https://finnhub.io/api/news?id=98868d0ea439aabb743b670acad40d9100051044327b0b3fbfddc987bdc152bf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Soar After Phase 3 Trial Success for Oral Type 2 Diabetes Pill",
    "summary": "Eli Lilly's oral GLP-1 drug achieved weight loss and A1C reduction goals in a key late-stage trial",
    "url": "https://finnhub.io/api/news?id=71aae19e197d0a8bfab5c5af41a30b3bbb09f3a2c4bdb202dd6a17c67ff132c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744900757,
      "headline": "Eli Lilly Shares Soar After Phase 3 Trial Success for Oral Type 2 Diabetes Pill",
      "id": 133958477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's oral GLP-1 drug achieved weight loss and A1C reduction goals in a key late-stage trial",
      "url": "https://finnhub.io/api/news?id=71aae19e197d0a8bfab5c5af41a30b3bbb09f3a2c4bdb202dd6a17c67ff132c0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock soars on positive weight-loss pill results",
    "summary": "Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=fd984a41f8adf2dc5628856afe6c30970797c9c9327cfe338b41174be1184726",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744899506,
      "headline": "Eli Lilly stock soars on positive weight-loss pill results",
      "id": 133958478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=fd984a41f8adf2dc5628856afe6c30970797c9c9327cfe338b41174be1184726"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success",
    "summary": "Investing.com -- Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.",
    "url": "https://finnhub.io/api/news?id=6f05e1face6d2a2091b799194877fef323df0dc96258e2305cab4a087a474f70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744898871,
      "headline": "Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success",
      "id": 133958479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.",
      "url": "https://finnhub.io/api/news?id=6f05e1face6d2a2091b799194877fef323df0dc96258e2305cab4a087a474f70"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly shares climb on positive topline data for weight-loss pill",
    "summary": "Eli Lilly shares climb on positive topline data for weight-loss pill",
    "url": "https://finnhub.io/api/news?id=9df8adb55c77c0210e8fba50b02b9309a8ba8dbc0f7a0d2e595eafbbac8cf5eb",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744898840,
      "headline": "Eli Lilly shares climb on positive topline data for weight-loss pill",
      "id": 133945435,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9df8adb55c77c0210e8fba50b02b9309a8ba8dbc0f7a0d2e595eafbbac8cf5eb"
    }
  },
  {
    "ts": null,
    "headline": "Update: Eli Lilly Shares Rise as Potential Diabetes Treatment Meets Primary, Secondary Endpoints",
    "summary": "(Updates to include Eli Lilly's recent stock move in the headline and first paragraph.) Eli Lilly",
    "url": "https://finnhub.io/api/news?id=f159ee69adc4d117f850b672242c12dbae9e69fbc22c6cd3f61c6c20d987089c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744898775,
      "headline": "Update: Eli Lilly Shares Rise as Potential Diabetes Treatment Meets Primary, Secondary Endpoints",
      "id": 133958480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates to include Eli Lilly's recent stock move in the headline and first paragraph.) Eli Lilly",
      "url": "https://finnhub.io/api/news?id=f159ee69adc4d117f850b672242c12dbae9e69fbc22c6cd3f61c6c20d987089c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly confirms date and conference call for first-quarter 2025 financial results announcement",
    "summary": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://finnhub.io/api/news?id=b60855e77947f5a1ecbf3b2904b3ac5cca1719591810744a4c55dbaf9d78e0ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744898400,
      "headline": "Lilly confirms date and conference call for first-quarter 2025 financial results announcement",
      "id": 133958481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
      "url": "https://finnhub.io/api/news?id=b60855e77947f5a1ecbf3b2904b3ac5cca1719591810744a4c55dbaf9d78e0ac"
    }
  },
  {
    "ts": null,
    "headline": "Lilly weight-loss pill works as well as Ozempic, shares surge",
    "summary": "Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals...",
    "url": "https://finnhub.io/api/news?id=dd744153be9c84f99f49a4d7bb393c7dd2f84d9cec3e97188f91124e52a46058",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744897640,
      "headline": "Lilly weight-loss pill works as well as Ozempic, shares surge",
      "id": 133957775,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals...",
      "url": "https://finnhub.io/api/news?id=dd744153be9c84f99f49a4d7bb393c7dd2f84d9cec3e97188f91124e52a46058"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
    "summary": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
    "url": "https://finnhub.io/api/news?id=d89de58e5898b61cd6dec99e31cc4401f1568e8c8026a14a83905925769e4770",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744897502,
      "headline": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
      "id": 133958177,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d89de58e5898b61cd6dec99e31cc4401f1568e8c8026a14a83905925769e4770"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rockets On Weight-Loss Pill Progress",
    "summary": "Eli Lilly stock shot higher as its pill-form weight loss drug candidate cleared one of several Phase III hurdles. VKTX and NVO traded lower.",
    "url": "https://finnhub.io/api/news?id=be152b3414674355c74cf6bd09d18cbe5892da5b2425e16d2cdf83a1570505c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744893273,
      "headline": "Eli Lilly Stock Rockets On Weight-Loss Pill Progress",
      "id": 133942475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock shot higher as its pill-form weight loss drug candidate cleared one of several Phase III hurdles. VKTX and NVO traded lower.",
      "url": "https://finnhub.io/api/news?id=be152b3414674355c74cf6bd09d18cbe5892da5b2425e16d2cdf83a1570505c0"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly and Company (LLY) Is Among the Best Blue Chip Stocks to Buy According to Billionaires",
    "summary": "We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy according to billionaires. Is A Potential Trade War on the Horizon? The US […]",
    "url": "https://finnhub.io/api/news?id=4e971f88911ebe40be3bf3ff9b206c95a91f2ca48fee5cb426908a1595494710",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744892446,
      "headline": "Why Eli Lilly and Company (LLY) Is Among the Best Blue Chip Stocks to Buy According to Billionaires",
      "id": 133942476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy according to billionaires. Is A Potential Trade War on the Horizon? The US […]",
      "url": "https://finnhub.io/api/news?id=4e971f88911ebe40be3bf3ff9b206c95a91f2ca48fee5cb426908a1595494710"
    }
  },
  {
    "ts": null,
    "headline": "Stock Futures Trim Gains as Trump Rebukes Powell: Markets Wrap",
    "summary": "(Bloomberg) -- US stock futures trimmed an advance after President Donald Trump berated Federal Reserve Chair Jerome Powell for being slow to cut interest rates.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire and Legal CostsS&P 500 contracts were 0.5% higher, wel",
    "url": "https://finnhub.io/api/news?id=4ef73ea9758b746944ed40fa2b75effb485866db9f45389957d5906ec7764cb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744892434,
      "headline": "Stock Futures Trim Gains as Trump Rebukes Powell: Markets Wrap",
      "id": 133942369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- US stock futures trimmed an advance after President Donald Trump berated Federal Reserve Chair Jerome Powell for being slow to cut interest rates.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire and Legal CostsS&P 500 contracts were 0.5% higher, wel",
      "url": "https://finnhub.io/api/news?id=4ef73ea9758b746944ed40fa2b75effb485866db9f45389957d5906ec7764cb3"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s",
    "summary": "(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire",
    "url": "https://finnhub.io/api/news?id=f8ffd3456f7535c95fa226cbc333cfd2e3700aeadf37c04bdacf608f6fe6c0f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744890933,
      "headline": "Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s",
      "id": 133942478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire",
      "url": "https://finnhub.io/api/news?id=f8ffd3456f7535c95fa226cbc333cfd2e3700aeadf37c04bdacf608f6fe6c0f4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly shares jump 12% on positive Phase 3 results for oral diabetes drug",
    "summary": "Investing.com -- Shares of Eli Lilly and Company (NYSE:LLY) surged 12.5% following the announcement of positive Phase 3 trial results for orforglipron, a pioneering oral medication for type 2 diabetes.",
    "url": "https://finnhub.io/api/news?id=c240c9d8ad9febedcaf00e64b58c11b4c75f4bd0e0e85ff2f5e0c467eac5b141",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744890384,
      "headline": "Eli Lilly shares jump 12% on positive Phase 3 results for oral diabetes drug",
      "id": 133942479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares of Eli Lilly and Company (NYSE:LLY) surged 12.5% following the announcement of positive Phase 3 trial results for orforglipron, a pioneering oral medication for type 2 diabetes.",
      "url": "https://finnhub.io/api/news?id=c240c9d8ad9febedcaf00e64b58c11b4c75f4bd0e0e85ff2f5e0c467eac5b141"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Obesity Pill Progress",
    "summary": "Wall Street Lunch: Obesity Pill Progress",
    "url": "https://finnhub.io/api/news?id=d26f4d35ff945022dc3f69aec98e8b942a3c024cd31b1d05a4aafc8a07f501b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744889760,
      "headline": "Wall Street Lunch: Obesity Pill Progress",
      "id": 133950467,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d26f4d35ff945022dc3f69aec98e8b942a3c024cd31b1d05a4aafc8a07f501b7"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Lilly point to 'internal battle' in stock market this earnings season",
    "summary": "UnitedHealth, Lilly point to 'internal battle' in stock market this earnings season",
    "url": "https://finnhub.io/api/news?id=0670731f7378144e75b971a119473a8d8193e9ed545343e15854dd0af69ca0d5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744889440,
      "headline": "UnitedHealth, Lilly point to 'internal battle' in stock market this earnings season",
      "id": 134052623,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Lilly point to 'internal battle' in stock market this earnings season",
      "url": "https://finnhub.io/api/news?id=0670731f7378144e75b971a119473a8d8193e9ed545343e15854dd0af69ca0d5"
    }
  },
  {
    "ts": null,
    "headline": "Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade",
    "summary": "Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade",
    "url": "https://finnhub.io/api/news?id=94a1da4effa3fd9dbcf72ac97a87f782f5b9a3cfcce4408eb37a2738f415f516",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744888075,
      "headline": "Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade",
      "id": 133947861,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=94a1da4effa3fd9dbcf72ac97a87f782f5b9a3cfcce4408eb37a2738f415f516"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Potential Diabetes Treatment Meets Primary, Secondary Endpoints",
    "summary": "Eli Lilly (LLY) said Thursday that its drug orforglipron met primary and secondary endpoints compare",
    "url": "https://finnhub.io/api/news?id=6bccbec95783fa46e71c14e523272130c6b3791a57dc9e189497c885b78e8ec9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744887921,
      "headline": "Eli Lilly Potential Diabetes Treatment Meets Primary, Secondary Endpoints",
      "id": 133942480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Thursday that its drug orforglipron met primary and secondary endpoints compare",
      "url": "https://finnhub.io/api/news?id=6bccbec95783fa46e71c14e523272130c6b3791a57dc9e189497c885b78e8ec9"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's pill helps diabetes patients lose 7.9% weight in crucial study",
    "summary": "The results exceeded Wall Street targets and pushed the U.S. drugmaker's shares up 11% in premarket trading, while dragging down rival Novo Nordisk and obesity drug developer Viking Therapeutics.  Several companies are developing weight-loss pills, encouraged by estimates that sales of obesity treatments could hit $150 billion in the coming years.  Lilly, which has started stockpiling supplies of the pill, said it planned to file by the end of this year with global regulators for approval.",
    "url": "https://finnhub.io/api/news?id=cf851f018c7d55aa82e33e52cf807a3a0f478828cb5a7ce40dd9f754d9d0deee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744887026,
      "headline": "Lilly's pill helps diabetes patients lose 7.9% weight in crucial study",
      "id": 133942481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The results exceeded Wall Street targets and pushed the U.S. drugmaker's shares up 11% in premarket trading, while dragging down rival Novo Nordisk and obesity drug developer Viking Therapeutics.  Several companies are developing weight-loss pills, encouraged by estimates that sales of obesity treatments could hit $150 billion in the coming years.  Lilly, which has started stockpiling supplies of the pill, said it planned to file by the end of this year with global regulators for approval.",
      "url": "https://finnhub.io/api/news?id=cf851f018c7d55aa82e33e52cf807a3a0f478828cb5a7ce40dd9f754d9d0deee"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch",
    "summary": "In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or obese people by ...",
    "url": "https://finnhub.io/api/news?id=05c5cb3c6b44c92e96caf5b3abf714cb850d263c29c9ac486cdd50f45681eaf8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744886726,
      "headline": "Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch",
      "id": 133942482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or obese people by ...",
      "url": "https://finnhub.io/api/news?id=05c5cb3c6b44c92e96caf5b3abf714cb850d263c29c9ac486cdd50f45681eaf8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results",
    "summary": "The first GLP-1 weight-loss pill is a step closer to hitting the market.  Eli Lilly  said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs closer to patients seeking to lose weight.  Physicians and patients have been hoping for pill versions of popular GLP-1s for weight loss.",
    "url": "https://finnhub.io/api/news?id=180a7639bee38ac7d3ff87e73e55e79cf7d2b212762e1622fc11d15f642928cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744886700,
      "headline": "Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results",
      "id": 133942484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The first GLP-1 weight-loss pill is a step closer to hitting the market.  Eli Lilly  said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs closer to patients seeking to lose weight.  Physicians and patients have been hoping for pill versions of popular GLP-1s for weight loss.",
      "url": "https://finnhub.io/api/news?id=180a7639bee38ac7d3ff87e73e55e79cf7d2b212762e1622fc11d15f642928cb"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to",
    "url": "https://finnhub.io/api/news?id=df724be30cb8ab2ae770c6739cd4823e1cd5ce1c2a00c1b17946900565e85dd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744886700,
      "headline": "Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial",
      "id": 133942483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to",
      "url": "https://finnhub.io/api/news?id=df724be30cb8ab2ae770c6739cd4823e1cd5ce1c2a00c1b17946900565e85dd6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
    "summary": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
    "url": "https://finnhub.io/api/news?id=99271e7159f2452ff254a1f3d8690c362475c0555a59baf0798a2fe751bb5b2e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744885080,
      "headline": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
      "id": 133945452,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
      "url": "https://finnhub.io/api/news?id=99271e7159f2452ff254a1f3d8690c362475c0555a59baf0798a2fe751bb5b2e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly pill helps diabetes patients lose weight by nearly 8%, shares surge",
    "summary": "Eli Lilly's experimental pill led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial, the company said on Thursday. ...",
    "url": "https://finnhub.io/api/news?id=381ed772a85d0defc7d6053f6d0e5736fc4cd8fe908b425faa5ddc84bd9352bf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744882553,
      "headline": "Lilly pill helps diabetes patients lose weight by nearly 8%, shares surge",
      "id": 133944196,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly's experimental pill led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial, the company said on Thursday. ...",
      "url": "https://finnhub.io/api/news?id=381ed772a85d0defc7d6053f6d0e5736fc4cd8fe908b425faa5ddc84bd9352bf"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results",
    "summary": "By Robb M. Stewart Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. ...",
    "url": "https://finnhub.io/api/news?id=939bbeb5eb4e9d365f19770abcfc26eb41e9f041f954270cb11b1a213e0c457e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744876389,
      "headline": "Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results",
      "id": 133941987,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Robb M. Stewart Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. ...",
      "url": "https://finnhub.io/api/news?id=939bbeb5eb4e9d365f19770abcfc26eb41e9f041f954270cb11b1a213e0c457e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s stock soars as successful trial of weight-loss pill is a game changer",
    "summary": "Eli Lilly’s stock soars as successful trial of weight-loss pill is a game changer",
    "url": "https://finnhub.io/api/news?id=a18d55d7057d12f92ffbb8f3e03ce85d7d4fdd002f94cf75e78ac8c8cb70806a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744876080,
      "headline": "Eli Lilly’s stock soars as successful trial of weight-loss pill is a game changer",
      "id": 133945453,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s stock soars as successful trial of weight-loss pill is a game changer",
      "url": "https://finnhub.io/api/news?id=a18d55d7057d12f92ffbb8f3e03ce85d7d4fdd002f94cf75e78ac8c8cb70806a"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Up in Premarket Trading; UnitedHealth Group, Humana Lag",
    "summary": "S&P 500 Futures Up in Premarket Trading; UnitedHealth Group, Humana Lag",
    "url": "https://finnhub.io/api/news?id=cca4497737c5fc12b8802bc4e6d865fa47933ddf5ed019cdb403edc90efc21e0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744875000,
      "headline": "S&P 500 Futures Up in Premarket Trading; UnitedHealth Group, Humana Lag",
      "id": 133945455,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "S&P 500 Futures Up in Premarket Trading; UnitedHealth Group, Humana Lag",
      "url": "https://finnhub.io/api/news?id=cca4497737c5fc12b8802bc4e6d865fa47933ddf5ed019cdb403edc90efc21e0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly pill leads to 7.9% weight loss in late-stage trial, shares jump",
    "summary": "Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and lowered blood sugar for overweight patients with type 2 diabetes in a...",
    "url": "https://finnhub.io/api/news?id=01aa0a50151512eacacf6a92d6b882b67f3aeff61a40b0074049a479a20b08bb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744872961,
      "headline": "Lilly pill leads to 7.9% weight loss in late-stage trial, shares jump",
      "id": 133941627,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and lowered blood sugar for overweight patients with type 2 diabetes in a...",
      "url": "https://finnhub.io/api/news?id=01aa0a50151512eacacf6a92d6b882b67f3aeff61a40b0074049a479a20b08bb"
    }
  }
]